News Focus
News Focus
icon url

Number sleven

11/04/23 6:59 PM

#417678 RE: Bouf #417673

Bouf, I understand your skepticism. The generic companies purchase API. They don't produce it. If Amarin can continue to open non US markets they should be able to establish a pricing advantage in the US. If a cheaper production method is discovered it wouldn't necessarily provide either side advantage.
Sleven,